TABLE 3.

A few examples of chitosan based other therapeutic agents nanoparticles and their application in oncotherapies over the last decades.

Agents	Application	Results	References
FA-CS	Breast cancer	Improved delivering capacity to cancer cells through ligand-receptor dependent and independent cellular engulfment	Nemati et al. (2021)
GA-CS	Hepatocellular carcinoma	Through enhancing intracellular delivery and uptake to improve both antitcancer efficacy and safety	Hefnawy et al. (2020)
HER2-Gem-CS	Pancreatic cancer	Showed superior anti-proliferative activity and enhanced S-phase arrest due to higher cellular binding and prolonged intracellular retention	Arya et al. (2011)
CNPs-Ce6	Lung cancer cells	Attenuated its cytotoxicity but improved its therapeutic efficacy by preventing serum absorption and prolonging the blood circulation time	Ding et al. (2018)
CS-TPP/IL-12	Colorectal cancer	Attenuated the toxicity of IL-12 and inhibited tumor metastasis by inducing NK cells and T cells infiltration	Xu et al. (2012)
HMSNs-CS-DOX- CuS	Breast cancer	Site-specific release of DOX under the tumor microenvironment, preventing release into circulation	Niu et al. (2021)
Erlotinib- CNPs	Lung cancer cells	Released erlotinib slowly in comparison to the marketed tablet formulation	Saravanakumar et al. (2020)
Gd-CS-OA/Ce6	Breast cancer	Demonstrated promising application in situ 4T1 tumor model	Zhao et al. (2020)

FA-CS, folic acid conjugated chitosan nanoparticle; GA-CS NPs, glycyrrhetinic acid-conjugated chitosan nanoparticle; HER2-Gem-CS, herceptin (HER2)-conjugated gemcitabine-loaded chitosan nanoparticle; CNPs-Ce6, Chlorin e6 chitosan nanoparticles; CS-TPP/IL-12, chitosan-tripolyphosphate interleukin-12; HMSNs-CS-DOX-CuS, hollow mesoporous silica nanoparticles chitosan doxorubicin and copper sulfide; Gd-CS-OA/Ce6, gadopentetic acid chitosan octadecanoic acid/chlorin e6.